Treatment of bone pain secondary to metastases using samarium-153-EDTMP
Keywords:
Samarium, Pain, Metastasis, Breast cancer, Prostate cancerAbstract
CONTEXT: More than 50% of patients with prostate, breast or lung cancer will develop painful bone metastases. The purpose of treating bone metastases is to relieve pain, reduce the use of steroids and to maintain motion. OBJECTIVE: To evaluate the use of samarium-153- EDTMP (153Sm-EDTMP) for the treatment of bone pain secondary to metastases that is refractory to clinical management. TYPE OF STUDY: Retrospective. SETTING: Division of Nuclear Medicine, Universidade Estadual de Campinas (Unicamp). METHODS: Fifty-eight patients were studied (34 males) with mean age 62 years; 31 patients had prostate cancer, 20 had breast cancer, three had lung cancer, one had lung hemangioendothelioma, one had parathyroid adenocarcinoma, one had osteosarcoma and one had an unknown primary tumor. All patients had multiple bone metastases demonstrated by bone scintigraphy using 99mTcMDP,and were treated with 153Sm-EDTMP. Response to treatment was graded as good (pain reduction of 50-100%), intermediate (25-49%) and poor (0-24%). RESULTS: All patients showed good uptake of 153Sm-EDTMP by bone metastases. Among the patients with prostate cancer, intermediate or good response to therapy occurred in 80.6% (25 patients) and poor response in 19.4% (6). Among the patients with breast cancer, 85% (17) showed intermediate or good response to therapy while 15% (3) showed poor response. All three patients with lung cancer showed poor response to treatment. The lung hemangioendothelioma and unknown primary lesion patients showed intermediate response to treatment; the osteosarcoma and parathyroid adenocarcinoma patients showed good response to treatment. No significant myelotoxicity occurred. DISCUSSION: Pain control is important for improving the quality of life of patients with advanced cancers. The mechanism by which pain is relieved with the use of radionuclides is still not yet completely understood, however, the treatment is simple and provides a low risk of mielotoxicity. CONCLUSION: Treatment with 153Sm-EDTMP can control the pain secondary to bone metastases effectively in most patients with breast and prostate cancer without significant side effects.
Downloads
References
Holmes RA. [153Sm] EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992;22(1):41-5.
Silberstein E. Treatment of the pain of bone metastases. In: Collier BD, Fogelman I, Rosenthal L, editors. Skeletal Nuclear Medicine. St. Louis: Mosby Year Book; 1996. p. 468-74.
Campa JA 3rd, Payne R. The management of intractable bone pain: a clinician’s perspective. Semin Nucl Medicine. 1992;22 (1):3-10.
Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33(10):1583-91.
Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34(11):1839-44.
Bouchet LG, Bolch WE, Goddu SM, Howell RW, Rao DV. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med. 2000;41(4):682-7.
Saarto T, Janes R, Tenhunen M, Kouri M. Palliative radio- therapy in the treatment of skeletal metastases. Eur J Pain. 2002;6(5):323-30.
Serafini AN. Therapy of metastatic bone pain. J Nucl Med. 2001;42(6):895-906.
Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34(7):1031-6.
Turner JH, Martindale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15(12):784-95.
McEwan AJ. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol. 2000;10(2):103-14.
Serafini AN. Systemic metabolic radiotherapy with samarium- 153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med. 2001;45(1):91-9.
Lovera C, Massardo T, Galleguillos MC, et al. Respuesta analgésica y efectos secundarios en pacientes con metástasis osteoblásticas tratados con Samario-153 etilendiaminotetra- metilenfosfato. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate]. Rev Med Chil.1998;126(8):963-71.
Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose of samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26(1):2-7.
Menda Y, Bushnell DL, Williams RD, Miller S, Thomas MO. Efficacy and safety of repeated samarium-153 lexidronam treat- ment in a patient with prostate cancer and metastatic bone pain. Clin Nucl Med. 2000;25(9):698-700.
Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phospho- nate. Eur J Cancer. 1991;27(9):1084-6.
George B, Douard MC, Rain JD. Radiothérapie métabolique: quel rôle en 2001?. [Metabolic radiotherapy: what role will it have in 2001?] Cancer Radiother. 2002;6(3):188-200.
Krishnamurthy GT, Krishnamurthy S. Radionuclides for meta- static bone pain palliation: a need for rational re-evaluation in the new millennium. J Nucl Med. 2000;41(4):688-91.
